Intellia Therapeutics Stock Today
| NTLA Stock | USD 10.71 0.80 6.95% |
PerformanceVery Weak
| Odds Of DistressLow
|
Intellia Therapeutics is trading at 10.71 as of the 26th of February 2025, a 6.95 percent decrease since the beginning of the trading day. The stock's open price was 11.51. Intellia Therapeutics has less than a 15 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Note, on October 30, 2021, Representative Donald S Beyer Jr of US Congress acquired under $15k worth of Intellia Therapeutics's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of May 2016 | Category Healthcare | Classification Health Care |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 101.85 M outstanding shares of which 24.06 M shares are now shorted by private and institutional investors with about 7.64 trading days to cover. More on Intellia Therapeutics
Moving against Intellia Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Intellia Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | John MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIntellia Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Intellia Therapeutics' financial leverage. It provides some insight into what part of Intellia Therapeutics' total assets is financed by creditors.
| |||||
Intellia Therapeutics (NTLA) is traded on NASDAQ Exchange in USA. It is located in 40 Erie Street, Cambridge, MA, United States, 02139 and employs 526 people. Intellia Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.09 B. Intellia Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 101.85 M outstanding shares of which 24.06 M shares are now shorted by private and institutional investors with about 7.64 trading days to cover.
Intellia Therapeutics currently holds about 874.28 M in cash with (394.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Intellia Therapeutics Probability Of Bankruptcy
Ownership AllocationIntellia Therapeutics has a total of 101.85 Million outstanding shares. The majority of Intellia Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intellia Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intellia Therapeutics. Please pay attention to any change in the institutional holdings of Intellia Therapeutics as this could imply that something significant has changed or is about to change at the company. On October 30, 2021, Representative Donald S Beyer Jr of US Congress acquired under $15k worth of Intellia Therapeutics's common stock.
Check Intellia Ownership Details
Intellia Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Contrarius Investment Management Ltd | 2024-09-30 | 2 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2 M | |
| Casdin Capital, Llc | 2024-12-31 | 2 M | |
| Two Sigma Advisers, Llc | 2024-12-31 | 2 M | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 2 M | |
| Two Sigma Investments Llc | 2024-12-31 | 1.8 M | |
| Ubs Group Ag | 2024-12-31 | 1.7 M | |
| Voloridge Investment Management, Llc | 2024-12-31 | 1.5 M | |
| Pictet Asset Manangement Sa | 2024-09-30 | 1.4 M | |
| Ark Investment Management Llc | 2024-12-31 | 12.5 M | |
| Blackrock Inc | 2024-12-31 | 10.9 M |
Intellia Therapeutics Historical Income Statement
Intellia Stock Against Markets
Intellia Therapeutics Corporate Management
| JD Esq | General VP | Profile | |
| Jennifer Doudna | Founder Board | Profile | |
| Derek Hicks | Executive Officer | Profile | |
| Andrew May | Founder Board | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.